Viral hepatitis

Outlook on the Automated Cell Counters Global Market to 2028 - Use of Cell Counters in Personalized Medicine Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Monday, October 3, 2022
General Health, Science, Health, Research, Inflammation, Chronic condition, Tuberculosis, Cancer, Workforce, Degenerative disease, Joint United Nations Programme on HIV/AIDS, Conditional sentence, Viral hepatitis, Parasitism, Profile, Research, Prevalence, Man, Knowledge, Diagnosis, World Health Organization, Fungus, Liver, WHO, Virus, CAGR, Center, Death, COVID-19, Infection, Growth, Korea Disease Control and Prevention Agency, Cancer Research UK, HIV, Bacteria, TB, Ageing, Hepatitis, CDC, Method, Biotechnology, Globe, UNAIDS, Woman, Pathogen, HIV/AIDS, Pharmaceutical industry, Vaccine

Additionally, advancement in automated cell counters is likely to emerge as a significant trend in the market during the forecast period.

Key Points: 
  • Additionally, advancement in automated cell counters is likely to emerge as a significant trend in the market during the forecast period.
  • Therefore, the rising prevalence of infectious and chronic diseases across the globe is driving the growth of the automated cell counters market.
  • With technological advancements in automated cell counters and a rise in application areas of the instrument, there has been a shift in usage of automated cell counters.
  • Thus, a lack of a skilled workforce who can easily use these instruments is hampering the growth of the automated cell counters market.

Aligos Therapeutics Files Response to Janssen Biopharma Lawsuit and Lodges Counterclaims Alleging Unfair Competition and Promissory Fraud

Retrieved on: 
Wednesday, September 28, 2022
ASO, University, Hepatitis, Therapy, Doctor of Philosophy, COVID-19, Sirna, Institute of Liver and Biliary Sciences, County, Oligonucleotide, NASH, Publication, Liver disease, CHB, HBV, Degenerative disease, Forward-looking statement, U.S. Securities and Exchange Commission, CEO, Hepatitis B virus, MBA, Terminology, Nasdaq, Fatty liver disease, Superior court, Viral hepatitis, Private Securities Litigation Reform Act, Drug development, SAN, Biotechnology, Security (finance), Janssen, GLOBE, Management, Jacob Aligo

The response further outlines and documents that all work was performed by Aligos employees after leaving Janssen Biopharma.

Key Points: 
  • The response further outlines and documents that all work was performed by Aligos employees after leaving Janssen Biopharma.
  • The counterclaims against Janssen allege that Janssen has engaged in unfair competition and promissory fraud.
  • Aligos co-founders, Lawrence M. Blatt, Ph.D., MBA, and Leonid Beigelman, Ph.D., joined Aligos in filing the counterclaims.
  • The facts are on Aligos side, and we will continue to defend ourselves from the baseless allegations made by Janssen.

American Liver Foundation Hosts Free Liver Cancer Conference for Patients and Families

Retrieved on: 
Tuesday, September 27, 2022
Squamous cell carcinoma, Viral hepatitis, MPH, Liver cancer, Infection, American Liver Foundation, Football, Rib cage, Liver disease, Center, Blood, Cornell University, Institute of Liver and Biliary Sciences, Knowledge, Hope, California Pacific Medical Center, Digestion, Population, Life, Obesity, News, Doctor of Public Health, Education, Rush University Medical Center, Patient, MS, NAFLD, HCC, Bile, Hepatitis, Glycogen, Cancer, Cholangiocarcinoma, MBA, Fatty liver disease, Liver, Tissue, Degenerative disease, Yale University, Korea Disease Control and Prevention Agency, Caregiver, Liver function tests, Research, Conference, Bristol Myers Squibb, Memorial Sloan Kettering Cancer Center, University, University of Florida Health, Hepatocellular carcinoma, Residential care, Dietary supplement, Pharmaceutical industry, MD, Exelixis, Genentech

FAIRFIELD, N.J., Sept. 27, 2022 /PRNewswire/ -- The American Liver Foundation is pleased to host its third annual, The Educated Patient: A Liver Cancer Conference Presented by Exelixis on October 7th and 8th from 11AM to 2PM ET. This two-day virtual education program is created especially for liver cancer patients and their family members or caregivers. Patients, caregivers and family members can register for free.

Key Points: 
  • The Educated Patient: A Liver Cancer Conference Presented by Exelixis offers presentations, workshops and opportunities for engagement with leading medical experts, researchers and others knowledgeable about the issues most relevant to those dealing with liver cancer .
  • "Living with liver cancer can be an isolating and confusing experience," said Lorraine Stiehl, Chief Executive Officer, American Liver Foundation.
  • "We are looking forward to the 3rd Annual Liver Cancer Conference for patients and caregivers.
  • The mission of the American Liver Foundation isto promote education, advocacy, support services and research for the prevention, treatment and cure of liver disease.

Gilead Joins First-of-its-Kind Public-Private Initiative to Improve Management of Viral Hepatitis in Vietnam and the Philippines

Retrieved on: 
Thursday, September 22, 2022
Biotechnology, Infectious Diseases, Hospitals, Health, Pharmaceutical, MPH, Viral hepatitis, Cirrhosis, Health, Hepatitis, UN, Sustainable development, Sustainable Development Goals, Hepatitis C, Twitter, Beth Israel Deaconess Medical Center, Hospital, Conditional sentence, SDG 3, World Health Organization, World, Organization, United Nations, HIV, Population, Hepatitis B, Liver cancer, Partnership, Social change, Gilead Sciences, Internal medicine, Program, Cancer, Global health, Biomedical technology, Diagnosis, Infection, WHO, Harvard Medical School, Science, University of the Philippines Manila, Medicine, CDA, Mortality, Lists of countries and territories, University, Education, SDG, First Nations in Ontario, Pharmaceutical industry, Vaccine, MD, Brigham

The two organizations will make the outcomes and learnings from the initiative public to contribute towards better understanding of adequate public health approaches to improve person-centered, community-based management of viral hepatitis.

Key Points: 
  • The two organizations will make the outcomes and learnings from the initiative public to contribute towards better understanding of adequate public health approaches to improve person-centered, community-based management of viral hepatitis.
  • The initiative will support national priorities for Vietnam and the Philippines: both governments are committed to strengthening primary healthcare and controlling hepatitis.
  • For more information about Gilead, please visit the companys website at www.gilead.com , follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
  • 1 WHO Global Health Sector Strategy on Viral Hepatitis 2016-201: Towards Ending Viral Hepatitis https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-...

Vir Biotechnology Announces First Patient Dosed in the Phase 2 SOLSTICE Trial Evaluating VIR-2218 and VIR-3434 for the Treatment of Chronic Hepatitis D Virus Infection

Retrieved on: 
Thursday, September 22, 2022
Adult, Half-life, Safety, COVID-19, Sirna, Risk, Virus, Blood, ALT, U.S. Securities and Exchange Commission, HBsAg, Week, Coinfection, Viremia, Liver cancer, Private Securities Litigation Reform Act, Hepatitis B, HBV, Forward-looking statement, Alanine transaminase, Patient, Clinical trial, Drug development, Disease, Hepatitis B virus, Technology, HIV, Therapeutic index, Viral hepatitis, RNA, Research, GLOBE, Hepatocyte, HDV, Superinfection, Mortality, Immune system, Monoclonality, Infection, Death, Hepatocellular carcinoma, Vaccine, Pharmaceutical industry

SAN FRANCISCO, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in the Phase 2 SOLSTICE clinical trial evaluating VIR-2218 and VIR-3434 as monotherapy and in combination for the treatment of people living with chronic hepatitis D virus (HDV), which occurs as a simultaneous co-infection or super-infection alongside hepatitis B virus (HBV). HDV infection, the most aggressive form of viral hepatitis, increases the risk of poor outcomes, including liver cancer and death, compared with HBV alone.

Key Points: 
  • VIR-2218 and VIR-3434 are currently being evaluated for the treatment of HBV in the Phase 2 MARCH (Monoclonal Antibody siRNA Combination against Hepatitis B) trial.
  • Chronic hepatitis D virus (HDV) infection occurs as a simultaneous co-infection or super-infection with hepatitis B virus (HBV).
  • Chronic hepatitis B virus (HBV) infection remains an urgent global public health challenge associated with significant morbidity and mortality.
  • Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B and hepatitis D viruses, influenza A and human immunodeficiency virus.

LiverMultiScan Shown to Be a Cost-Effective Alternative to Liver Biopsies for Monitoring Patients with Autoimmune Hepatitis

Retrieved on: 
Wednesday, September 21, 2022
Managed Care, Hospitals, Health, Medical Devices, Chronic liver disease, BMJ Open, Health, Precision medicine, Safety, NHS, 5-1-1, Oxford University Hospitals NHS Foundation Trust, Doctor of Philosophy, Autoimmune hepatitis, Woman, Magnetic resonance, McKay, Liver disease, MRI, Incidence, Patient, Genetics, Cancer, Physician, Technology, Systematic review, Fatty liver disease, Liver, Viral hepatitis, Diagnosis, Meta-analysis, AIH, Research, Hepatitis, Immune system, Innovation, Live Damage, Master of Science, Conditional sentence, Digestive Diseases and Sciences, Medical imaging, MBBS

Noninvasive imaging with LiverMultiScan can detect the presence and extent of liver fibro-inflammation in a risk-free manner, resulting in reduced liver biopsy frequency for AIH patients, noted Mamta Bajre, MBBS, M.Sc.

Key Points: 
  • Noninvasive imaging with LiverMultiScan can detect the presence and extent of liver fibro-inflammation in a risk-free manner, resulting in reduced liver biopsy frequency for AIH patients, noted Mamta Bajre, MBBS, M.Sc.
  • By eliminating risks and complications associated with liver biopsy, LiverMultiScan helps improve patient outcomes and experience.
  • Although necessary for diagnosis, liver biopsy is not sustainable for long-term monitoring of patients with AIH.
  • LiverMultiScan is a novel technology that addresses a critical unmet need for noninvasive techniques to diagnose and monitor patients with chronic liver diseases such as nonalcoholic steatohepatitis, autoimmune hepatitis, or viral hepatitis.

American Liver Foundation and UPMC Launch New Video Series on Living Organ Donation

Retrieved on: 
Thursday, September 1, 2022
People, American Liver Foundation, UPMC Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Patient, University, Capitol Hill, Transplant, Cancer, Caregiver, Obesity, Research, Helpline, Bile, Degenerative disease, Social media, Liver, Institute of Liver and Biliary Sciences, UPMC, NAFLD, Rib cage, Liver disease, News, Outline of health sciences, Fatty liver disease, ALF, Blood, Physician, Liver transplantation, Diagnosis, Football, U.S. News & World Report, Education, Hospital, Glycogen, MD, Digestion, Viral hepatitis, Population, NASH, Life, Public policy, Dentistry, Dietary supplement, U.S

FAIRFIELD, N.J., Sept. 1, 2022 /PRNewswire/ -- The American Liver Foundation and UPMC have launched a new, five-part animated video series to help liver transplant patients find a living donor. A recent addition to a comprehensive Living Donor Liver Transplant Information Center launched in 2020, the newly created video series helps patients and families easily understand the steps they can take to help find a living donor.

Key Points: 
  • FAIRFIELD, N.J., Sept. 1, 2022 /PRNewswire/ -- The American Liver Foundation and UPMC have launched a new, five-part animated video series to help liver transplant patients find a living donor.
  • With living donor liver transplantation, a donor can give a portion of their liver to the patient.
  • The American Liver Foundation is the nation's largest non-profit organization focused solely on promoting liver health and disease prevention.
  • The mission of the American Liver Foundation isto promote education, advocacy, support services and research for the prevention, treatment and cure of liver disease.

Blood And Blood Components Global Market Report 2022: Growing Prevalence of Diseases and Increasing Numbers of Road Accidents and Traumas Driving Sector - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 31, 2022
Cardiology, Biotechnology, Surgery, Oncology, Health, Infectious Diseases, Hospitals, Other Health, WNV, Mortality, Blood transfusion, Safety, Application, Awareness, TTI, Accident, Collection, Blood, Infection, US, Male, HIV, Center, HTLV-III, Trauma, Viral hepatitis, Prevalence, Centers for Disease Control and Prevention, Risk, Haemophilia A, Growth, Injury, Patient, Medical device, Vaccine, EU, West Nile virus

The "Blood And Blood Components Global Market Report 2022, By Product, By End-Users, By Application, By Blood Components" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Blood And Blood Components Global Market Report 2022, By Product, By End-Users, By Application, By Blood Components" report has been added to ResearchAndMarkets.com's offering.
  • The growing prevalence of diseases and increasing numbers of road accidents and traumas are increasing the demand for blood and thus driving the market.
  • The blood and blood components market is restrained by the growing risk of developing or transferring an infection while the blood is transmitted to the patients.
  • The most prominent trend that has been witnessed in the blood and blood components market is the growing number of collaborations between the players involved in the market.

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2022 Financial Results

Retrieved on: 
Thursday, August 4, 2022
U.S. Securities and Exchange Commission, CEO, GLOBE, R, Investment, European Association for the Study of the Liver, Board, Security (finance), Center, Patient, KU Leuven, CTA, Protease, Drug design, CAM, G&A, Fatty liver disease, Infection, HBsAg, Degenerative disease, Terminology, ASO, CHB, Institute of Liver and Biliary Sciences, EASL, Congress, SAN, Safety, Doctor of Philosophy, Nasdaq, Pharmacokinetics, Medical research, HBeAg, PF-07321332, Forward-looking statement, EC50, NASH, Therapy, COVID-19, Cell, Program, Drug development, Â, Severe acute respiratory syndrome coronavirus 2, Rega Institute for Medical Research, Association, Sirna, Liver disease, Viral hepatitis, Hepatitis, Research, MBA, CD3, Private Securities Litigation Reform Act, Pharmaceutical industry, Vaccine, Jacob Aligo, Liver

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today reported recent business progress and financial results for the second quarter June 30, 2022.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today reported recent business progress and financial results for the second quarter June 30, 2022.
  • In the second quarter, we continued to make strong progress in advancing our drug candidates and discovery programs, said Lawrence Blatt, PhD, MBA, CEO and Chairman of the Board at Aligos.
  • ALG-000184 (CAM-2): Enrollment of HBeAg positive subjects in 28-day and 12-week cohorts evaluating various dose levels is ongoing.
  • We plan to share data from HBeAg positive cohorts at a scientific conference in Q4 2022.

Echosens Partners with World Hepatitis Alliance on World Hepatitis Day, July 28, Urges Importance of Testing and Treatment

Retrieved on: 
Thursday, July 28, 2022
Other Health, Software, Managed Care, Hardware, Oncology, Data Management, Medical Devices, Technology, Hospitals, Biotechnology, Practice Management, Health, Viral hepatitis, Awareness, Pioneer, Elastography, CEO, World, WHD, Fibrosis, Hepatitis, Degenerative disease, Liver disease, World Hepatitis Alliance, Organization, Inflammation, Liver, Liver cancer, Publication, Disease, Patient, Â, Vaccine

Echosens , a high-technology company offering liver diagnostic solutions, establishes its support of World Hepatitis Day (WHD), July 28 by partnering with the World Hepatitis Alliance as a bronze sponsor .

Key Points: 
  • Echosens , a high-technology company offering liver diagnostic solutions, establishes its support of World Hepatitis Day (WHD), July 28 by partnering with the World Hepatitis Alliance as a bronze sponsor .
  • The commemoration calls for greater awareness of the 357 million people who live with viral hepatitis but are unaware of it.
  • The campaigns theme I cant wait highlights the need to accelerate the fight against viral hepatitis and the importance of testing and treatment for the real people who need it.
  • Viral hepatitis is an inflammation of the liver and a major public health concern worldwide that until recently - has garnered little notice.